CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 762 enrolled
Drug / intervention
Phase 1: Olanzapine +9 moredrug
Likely dose
Phase 1: Olanzapine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03510325
NCT03510325Phase 3Completed

Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments

Shanghai Mental Health Center·interventional·Posted Apr 27, 2018·Updated Apr 8, 2025

In Brief

A Phase 3 clinical trial evaluating Phase 1: Olanzapine, Phase 1: Risperidone, and 8 other interventions for Schizophrenia. Completed, enrolled 762 participants across 7 sites.

Detailed Summary

This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and adverse reactions and pharmacoeconomic evaluation, this project intends to provide evidence for the selection of antipsychotics in FES patients as well as the efficacy and safety of using clozapine in the early phase of schizophrenia treatment by comparing with other SGAs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedApr 27, 2018
Enrollment StartFeb 12, 2019
Primary CompletionSep 27, 2023
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 8.2 years ago

Interventions

Phase 1: Olanzapinedrug

Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks

Phase 1: Risperidonedrug

Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks

Phase 1: Amisulpridedrug

Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks

Phase 1: Aripiprazoledrug

Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks

Phase 1: Perphenazinedrug

Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks

Phase 2: Olanzapinedrug

Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks

Phase 2: Amisulpridedrug

Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks

Phase 2: Clozapinedrug

Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks

Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapyother

Clozapine extended treatment: dosage: 200-600 mg/d; dosage form: po. Combined clozapine-MECT therapy: Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month.

Phase 3B: Clozapine or another SGAsdrug

Clozapine: Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2.